INVESTINGSarepta Therapeutics Surges on FDA Approval of Muscular Dystrophy TreatmentBy M. Corey Goldman
EARNINGSMylan Posts Stronger-Than-Expected Third-Quarter Profit, Reiterates ForecastBy M. Corey Goldman
INVESTINGAlphabet Is Cheap Now, but It Won't Remain This Inexpensive ForeverBy Michael Wiggins De Oliveira